Trial Profile

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Blinatumomab (Primary) ; Asparaginase; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Etoposide; Folinic acid; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Mitoxantrone; Pegaspargase; Tioguanine; Vincristine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Registrational; Therapeutic Use

13 Nov 2024 Planned End Date changed from 22 Sep 2024 to 18 Sep 2025.
26 Sep 2023 Planned End Date changed from 30 Apr 2024 to 22 Sep 2024.
31 May 2023 Primary endpoint (DFS of low risk (LR) relapse patients) has been met according result published in the Journal of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com